Keyphrases
Chronic Kidney Disease
99%
Core Outcome Set
99%
Clinical Trials
93%
Randomized Controlled Trial
66%
Sorafenib
33%
Risk Outcomes
33%
Patient Outcomes
33%
Risk-benefit
33%
Patient Benefit
33%
Drug Development
33%
Web-based Survey
33%
Clinical Perspective
33%
Patient Risk
33%
Sectional Analysis
33%
United States
33%
Meta-analysis
33%
Systematic Meta-analysis
33%
Osteoporosis
33%
Diverse Populations
33%
Health Outcomes
16%
FDA-approved Drugs
14%
Off-label Indications
14%
Literature Search
12%
Data Extraction
12%
Underrepresentation
12%
Race-ethnicity
12%
Trialists
12%
International Consortium
11%
Health Measurement
11%
Health-related Quality of Life
11%
Adverse Events
9%
Approved Indication
9%
Monotherapy
9%
Objective Response Rate
9%
Trial Strategy
8%
Policy Reform
8%
Progressive Conditions
7%
Patient-reported Health
7%
Modality-specific
7%
Treatment Quality
7%
Treatment Modalities
7%
Disease Burden
7%
Disease Research
7%
Medicine and Dentistry
Clinical Trial
100%
Chronic Kidney Disease
99%
Randomized Controlled Trial
66%
Cross Sectional Study
66%
Sorafenib
33%
Major Depressive Episode
33%
Health Outcomes
15%
Quality of Life
15%
Adverse Event
14%
Decision Making
11%
Malignant Neoplasm
9%
Monotherapy
9%
Diseases
5%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Chronic Kidney Failure
99%
Randomized Controlled Trial
66%
Sorafenib
33%
Drug Development
33%
Cross Sectional Study
33%
Diseases
17%
Adverse Event
14%
Malignant Neoplasm
14%
Monotherapy
9%
Prevalence
8%
